article thumbnail

The Issue with Reissue: PTE Edition

FDA Law Blog: Biosimilars

Merck applied for a patent term extension on the reissued patent, claiming the start of the regulatory review period as April 2004 and termination at the approval of the BRIDION NDA in December 2015. With this long regulatory review period, the PTO granted the statutory-maximum five-year patent term extension. The plain text of 35 U.S.C.

article thumbnail

Optimization of Pharmaceutical Dosage/ Formulation Chemistry

Pharmaceutical Development Group

Formulation chemistry is the systematic and step-by-step approach to pharmaceutical development. Nowadays, as the usage of medicines is increasing, pharmaceutical companies are more eager to bring manufacturing a new look in quality and performance. There are different tests to assess the quality of a pharmaceutical product.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Speaking of Medicine – Mid-Year OPDP Enforcement Review

Eye on FDA

There are two means of gaining insight into the agency’s thinking about regulatory issues related to promotional communications by pharmaceutical companies; one is through the issuance of guidance documents, the other is through enforcement. But when it comes to enforcement things have changed greatly over the years.

article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

Dr Andersson is a member of the joint steering committee for the collaboration with Ionis Pharma, Silence Therapeutics and JCR Pharmaceuticals focussed on discovery and development of nucleic acid and protein therapeutics.

RNA 59
article thumbnail

The evolution of cell therapy to address unmet medical needs

Drug Target Review

Also, many companies never reached the point where they received validation from big pharmaceutical companies. From 2002 until 2004, Mr Culley was Director of Business Development and Marketing for Immusol, Inc. Mr Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022.

article thumbnail

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

For instance, we can compare the data from the 2021 DESTINY gastric cancer trial using the ADC Trastuzumab Deruxtecan with data from a gastric cancer trial in 2004 using the small molecule Irinotecan. In both cases, the active ingredients are camptothecin-derived topoisomerase 1 inhibitors with similar proposed modes of action.

article thumbnail

How the AI revolution can accelerate early drug discovery

Drug Target Review

Training AI/ML tools to predict results of otherwise complex and time-consuming calculations is gaining traction in pharmaceutical R&D. To really benefit from AI, the pharmaceutical industry must be more open to data sharing. Research and Development in the Pharmaceutical Industry | Congressional Budget Office [Internet].

Drugs 105